In the BioHarmony Drug Report Database
Tolazoline
Priscoline (tolazoline) is a small molecule pharmaceutical. Tolazoline was first approved as Priscoline on 1985-02-22. It is used to treat arteriosclerosis obliterans, causalgia, peripheral vascular diseases, persistent fetal circulation syndrome, and raynaud disease amongst others in the USA. The pharmaceutical is active against alpha-2C adrenergic receptor, alpha-2B adrenergic receptor, and alpha-2A adrenergic receptor.
Trade Name
|
Priscoline |
|---|---|
Common Name
|
tolazoline |
ChEMBL ID
|
CHEMBL770 |
Indication
|
arteriosclerosis obliterans, causalgia, peripheral vascular diseases, persistent fetal circulation syndrome, raynaud disease, spasm, systemic scleroderma, thromboangiitis obliterans, thrombophlebitis |
Drug Class
|
Antihistamines/local vasoconstrictors (antazoline type) |
Image (chem structure or protein)